Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
fda
9
×
indiana blog main
indiana top stories
life sciences
national blog main
raleigh-durham blog main
9
×
raleigh-durham top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
clinical trials
eli lilly
cancer
ipo
novartis
teva pharmaceutical
amgen
crispr
drugs
lasmiditan
migraine research foundation
triptans
What
new
9
×
fda
bio
drug
roundup
approval
ipo
migraine
won
cancer
class
companies
crispr
decades
drugs
group
isn’t
life
medicines
million
oks
pharmaceutical
science
second
therapeutics
activity
acute
addresses
allogene
amgen
approvals
approved
arguments
bails
big
biogen
biopharma
biotechs
brand
bridgebio
Language
unset
Current search:
fda
×
new
×
" raleigh-durham blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines